<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755530</url>
  </required_header>
  <id_info>
    <org_study_id>B363</org_study_id>
    <secondary_id>H-20059243</secondary_id>
    <nct_id>NCT04755530</nct_id>
  </id_info>
  <brief_title>Fermented Dairy Products and The Metabolic Syndrome</brief_title>
  <acronym>FerMetS</acronym>
  <official_title>Matrix Characterization and Effects of Fermented Dairy Products on Liver Fat, Cardiometabolic Risk and Gut Microbiome in Males With Symptoms of Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Rica Wium Geiker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Food for Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Dairy Research Foundation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen, Department of Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted as a randomized controlled trial with four parallel arms&#xD;
      including four dairy products. We will investigate the health effects of including yogurt in&#xD;
      the diet through a 16-weeks intervention period among 100 volunteering males with symptoms of&#xD;
      the metabolic syndrome. The study has a total duration of 20 weeks as a wash out period of&#xD;
      four weeks will be initiated prior to the intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>16-week parallel randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Until the statistical analyses are performed, principal investigator and statistician are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fat</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of liver fat by Magnetic Resonance Imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measured by fasting cholesterol, HDL, LDL, Triglycerid and LDL fractions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measured by fasting ALAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measured by fasting blood pressure (automatic device)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measurments of microbiota (fecal spot samples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism (fasting samples)</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of fasting glucose, insulin, C-peptide, HbA1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism (5 hour oral glucose tolerance test)</measure>
    <time_frame>Week 16 (5 hour test)</time_frame>
    <description>Measurements of glucose, insulin and C-peptide during a 5 hour oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of fasting CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of fasting IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of fasting TNF-alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measurements of body weight (every week), height (stadiometer) (only at screening), waist and hip circumference (non-elastic tape), sagittal diameter (abdominal caliper) (only week 0 and 16) as wells as fat mass and fat free mass (whole body DXA scan) (only week 0 and 16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat disposition and pancreatic fat</measure>
    <time_frame>Change from Week 0 to week 16</time_frame>
    <description>Measurements of viceral, subcutaneous and pancreatic fat by Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolome</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measurement of metabolomic markers in blood, urine and feces</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measured by International Physical Activity Questionnaire (IPAQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measured by Pittsburg Sleep Quality Index (PSQI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Perceived stress</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measured by Perceived Stress Scale (PSS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Life quality</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Measured by Physical and mental life quality, Short Form-36 (SF-36)</description>
  </other_outcome>
  <other_outcome>
    <measure>The influence of initial glucose metabolism</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Statistical investigation of the effect of initial glucose metabolism on liver fat</description>
  </other_outcome>
  <other_outcome>
    <measure>The influence of initial gut microbiota</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Statistical investigation of the effect of initial microbiota assessed by fecal sample on liver fat</description>
  </other_outcome>
  <other_outcome>
    <measure>The influence of initial body composition</measure>
    <time_frame>Change from week -4 to week 16</time_frame>
    <description>Statistical investigation of the effect of initial body composition assessed by DXA scan on liver fat</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Overweight or Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Regular whole milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Substitution of a part of the habitual diet with 400 g/day of regular whole milk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yogurt with live bacteria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substitution of a part of the habitual diet with 400 g/day of yogurt with life bacteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yogurt with inactivated bacteria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substitution of a part of the habitual diet with 400 g/day of yogurt with inactivated bacteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acidified whole milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Substitution of a part of the habitual diet with 400 g/day of acidified whole milk</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular whole milk</intervention_name>
    <description>400 g/day of regular whole milk</description>
    <arm_group_label>Regular whole milk</arm_group_label>
    <other_name>Dairy product</other_name>
    <other_name>Milk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt with live bacteria</intervention_name>
    <description>400 g/day of yogurt with live bacteria</description>
    <arm_group_label>Yogurt with live bacteria</arm_group_label>
    <other_name>Fermented dairy product</other_name>
    <other_name>Yogurt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt with inactivated bacteria</intervention_name>
    <description>400 g/day of yogurt with inactivated bacteria</description>
    <arm_group_label>Yogurt with inactivated bacteria</arm_group_label>
    <other_name>Fermented dairy product</other_name>
    <other_name>Yogurt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acidified whole milk</intervention_name>
    <description>400 g/day of yogurt with acidified whole milk</description>
    <arm_group_label>Acidified whole milk</arm_group_label>
    <other_name>Dairy product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 30-70 years&#xD;
&#xD;
          -  BMI of 28-45 kg/m2&#xD;
&#xD;
          -  Abdominal obesity (defined as waist circumference &gt;102 cm)&#xD;
&#xD;
          -  Provided voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight changes +/- 5% in the past three months&#xD;
&#xD;
          -  Any diet, allergy or intolerance which results in not being able to follow the study&#xD;
             protocol&#xD;
&#xD;
          -  Contraindications related to MRI (pacemaker, stent, magnitic metal in the body,&#xD;
             claustrophobia, physiological diseases or a body weight &gt;160 kg)&#xD;
&#xD;
          -  History or diagnosis of diabetes&#xD;
&#xD;
          -  History or diagnosis of heart, liver, gastrointestinal or kidney disease&#xD;
&#xD;
          -  History or diagnosis of illness related to energy balance&#xD;
&#xD;
          -  History or diagnosis of eating disorders&#xD;
&#xD;
          -  Simultaneous blood donation for other purpose than this study (and one month before&#xD;
             initiating the study)&#xD;
&#xD;
          -  Simultaneous participation in other clinical intervention studies&#xD;
&#xD;
          -  Any other condition that judged by the investgator may interfere with the adherence to&#xD;
             the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Based on self-representation of gender identity</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina RW Geiker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen, Department of Nutrition, Exercise and Sports</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karoline Sandby, MSc</last_name>
    <phone>+45 35323377</phone>
    <email>ksa@nexs.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina RW Geiker, PhD</last_name>
    <phone>+45 3532 4060</phone>
    <email>geiker@nexs.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Copenhagen, Department of Nutrition, Exercise and Sports</name>
      <address>
        <city>Frederiksberg</city>
        <state>DK</state>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karoline Sandby, MSc</last_name>
      <phone>+45 35323377</phone>
      <email>ksa@nexs.ku.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nina RW Geiker, PhD</last_name>
      <phone>+45 35324060</phone>
      <email>geiker@nexs.ku.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Nina RW Geiker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nina Rica Wium Geiker</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dairy</keyword>
  <keyword>Liver fat</keyword>
  <keyword>Glucose metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

